Immune checkpoint inhibitors (ICIs) have dramatically updated tumor therapeutic regimens, including therapies targeting programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4). The gene discussed is CD274; the disease is neoplasm.